当前位置：
X-MOL 学术
›
JAMA Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Precision Colorectal Cancer Fecal Immunological Test Screening With Fecal-Hemoglobin-Concentration–Guided Interscreening Intervals
JAMA Oncology ( IF 28.4 ) Pub Date : 2024-05-09 , DOI: 10.1001/jamaoncol.2024.0961 Amy Ming-Fang Yen, Chen-Yang Hsu, Ting-Yu Lin, Chiu-Wen Su, Han-Mo Chiu, Tony Hsiu-Hsi Chen, Sam Li-Sheng Chen
JAMA Oncology ( IF 28.4 ) Pub Date : 2024-05-09 , DOI: 10.1001/jamaoncol.2024.0961 Amy Ming-Fang Yen, Chen-Yang Hsu, Ting-Yu Lin, Chiu-Wen Su, Han-Mo Chiu, Tony Hsiu-Hsi Chen, Sam Li-Sheng Chen
ImportanceGiven a gradient relationship between fecal hemoglobin (f-Hb) concentration and colorectal neoplasia demonstrated previously, using f-Hb–guided interscreening interval has increasingly gained attention in population-based fecal immunological test (FIT), but it is very rare to address how to implement such a precision strategy and whether it can economize the use of FIT and colonoscopy.ObjectiveTo demonstrate the applicability of personalized colorectal cancer (CRC) screening with f-Hb–guided screening intervals to reduce the number of FITs and colonoscopy with as equivalent efficacy as universal biennial screening equivalent efficacy as universal biennial screening.Design, Setting, and ParticipantsA retrospective cohort study for developing f-Hb–guided precision interscreening interval was conducted using data on a Taiwanese biennial nationwide FIT screening program that enrolled more than 3 million participants aged 50 to 74 years between 2004 and 2014. The cohort was followed up over time until 2019 to ascertain colorectal neoplasia and causes of death. A comparative study was further designed to compare the use of FIT and colonoscopy between the personalized f-Hb–guided group and the universal biennial screening group given the equivalent efficacy of reducing CRC-related outcomes.Main Outcomes and MeasurementsA spectrum of f-Hb–guided intervals was determined by using the Poisson regression model given the equivalent efficacy of a universal biennial screening. The use of FIT and colonoscopy for the pragmatic f-Hb-guided interval group was measured compared with the universal biennial screening group. Data analysis was performed from September 2022 to October 2023.ResultsUsing data from the 3 500 250 participants (mean [SD] age, 57.8 [6.0] years) enrolled in the Taiwanese biennial nationwide FIT screening program, an incremental increase in baseline f-Hb associated with colorectal neoplasia and CRC mortality consistently was observed. Participants with different f-Hb levels were classified into distinct risk categories. Various screening intervals by different f-Hb levels were recommended. Using the proposed f-Hb–guided screening intervals, it was found that the personalized method was imputed to reduce the number of FIT tests and colonoscopies by 49% and 28%, respectively, compared with the universal biennial screening.Conclusion and RelevanceThe gradient relationship between f-Hb and colorectal neoplasia and CRC mortality was used to develop personalized FIT screening with f-Hb–guided screening intervals. Such a precision interscreening interval led to the reduced use of FIT test and colonoscopy without compromising the effectiveness of universal biennial screening.
更新日期：2024-05-09
京公网安备 11010802027423号